Immunothérapie du mésothéliome

Malignant mesothelioma is a tumor in which the prognosis for chemotherapy often remains insufficient. A new path emerges: the anti-tumor immunotherapy. The idea is to activate an immune response with the implication of the cytotoxic T cells specifically directed against cancer cells. Several approaches are possible and my lab develops primarily two strategies: either the use of antigen presenting cells (dendritic cells) from the patient, activated ex vivo, and then injected back to the patient to induce a specific anti-tumor response, or the use of a recombinant measles vaccine injected intra-tumor or close to the tumor cells. The strain attenuated virus, which comprises the vaccine, is specifi cally directed against tumor cells and infection of the tumor cells induces a cell death by apoptosis and activation of the T lymphocyte response.